Masimo's $5.31 Arbitrage Gap Widens as Bridger Exits Before Takeover

The core event is clear. On February 17, Danaher announced it will acquire Masimo for $9.9 billion, paying $180 per share in cash. That offer represents a premium of 38.3% to Masimo's last close before the news. For investors, this is a straightforward arbitrage setup: a large, all-cash bid at a significant discount to the pre-announcement price, with the deal expected to close in the second half of 2026.

Yet the market's immediate reaction contains a conflicting signal. On the very same day Danaher made its offer, Bridger Management disclosed in an SEC filing that it had sold out its entire position in Masimo, liquidating a $7.06 million stake. This tactical exit by a known holder, occurring as the stock surged on the acquisition news, is a classic event-driven puzzle. It suggests some sophisticated players are pricing in near-term execution risk or regulatory friction, creating a potential mispricing.

The bottom line is a gap. The deal's mechanics are solid, backed by a major shareholder's support agreement. But the $7 million exit by Bridger Management highlights that even in a clear arbitrage, sentiment can fragment. This divergence between the firm offer and a specific holder's action is the tactical signal that the market may be overestimating the near-term hurdles, leaving room for a disciplined player to step in.

The Mechanics: The $5.31 Arbitrage Gap

The immediate mispricing is stark. On the day Danaher's offer was announced, Masimo's stock surged 34.22 percent to $174.69. That leaves a clear $5.31 gap between the current price and the $180 cash offer. For a disciplined arbitrageur, that's the core opportunity: a near-certain exit at a known price, with the stock still trading below the takeover level.

This gap is even more telling when viewed through the lens of timing. Bridger Management's full liquidation of its $7.06 million stake happened on the same day as the announcement, but before that 34% pop. By selling at a lower price, Bridger effectively captured a smaller premium. This suggests the fund's calculus was that the near-term execution risk-regulatory hurdles, integration complexity, or even a potential bid from a third party-was not fully priced into the stock's post-announcement surge. They exited before the market's euphoria set in, potentially signaling that the $5.31 gap is not just a technical detail but a reflection of real, near-term uncertainty.

The deal structure itself adds a layer of complexity. Under the terms, a Danaher subsidiary will merge with Masimo, which will become a wholly owned subsidiary of Danaher upon closing. Crucially, Masimo will continue to be a standalone business unit and brand within Danaher's Diagnostics segment. This is a common path for large conglomerates, aiming to preserve operational autonomy while gaining access to capital and scale. Yet, this integration is not frictionless. It requires navigating internal corporate processes, aligning cultures, and managing the transition-all of which can introduce delays or unforeseen costs. The market's initial 34% rally may be pricing in a smooth, swift integration, while Bridger's exit hints at a more cautious view of the path ahead.

Catalysts and Watchpoints

The tactical thesis hinges on a clear path to the $180 exit. The primary catalyst is the deal's closing, now expected in the second half of 2026. Any regulatory pushback or significant delay is the key near-term risk that could break the arbitrage. The market is currently pricing in a smooth process, but the $5.31 gap suggests some skepticism remains. Watch for any formal regulatory filings or statements from antitrust authorities that could signal friction.

A secondary, more nuanced watchpoint is Danaher's guidance for the first full year post-close. The company expects Masimo to add $0.15 to $0.20 to its adjusted diluted net earnings per share. This modest accretion figure is a critical benchmark. It implies the integration will be cost-neutral or slightly dilutive in the near term, which could temper Danaher's enthusiasm if early results miss. For Masimo shareholders, it confirms the deal is not a massive earnings windfall, but a steady, cash-accretive acquisition.

Finally, monitor insider activity for subtle signals of confidence. On March 11, Masimo's CEO, Catherine Szyman, exercised restricted stock units, a routine vesting event. However, she withheld 1,069 shares to cover tax obligations at a price of $175.47. This is not a sale, but it does represent a small, forced reduction in her personal stake. In context, it shows the CEO is not actively buying more stock at the current price, which is neutral. A pattern of consistent insider buying or selling would be more telling, but for now, the activity is consistent with standard compensation management.

The bottom line is a checklist. The deal must clear regulatory hurdles on schedule. Danaher's first-year EPS guidance must hold. And insider behavior should remain steady. Each of these points is a potential trigger for the stock to either close the gap or widen it.